The multiple functions and activities of host defence peptides, described in the reviews of this theme issue are presented. The picture also illustrates LL-37 (upper) and β-defensin 1. (PDB ID 2K60 and 1IJV, respectively)
Adverse Cutaneous Drug Eruptions

Lars E. French

Contents
Preface: French, L.E.

Acute Generalized Exanthematous Pustulosis: Sokoll, A.
Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Mockenhaupt, A.F.
Genetics and the Potential for Predictive Tests in Adverse Drug Reactions: Pengelhoo, H.F.
Epilogue: Adverse Drug Reactions: Happel, B.

Editor: Lars E. French

Drug eruptions, ranging from epidemiology and pathogenesis to clinical presentations and management, are a significant concern in the health care system. In this book, a selected group of experts provide an up-to-date, condensed, and clinically relevant overview of the field of cutaneous drug eruptions, ranging from epidemiology and genetic predisposition to available therapeutic measures, including rapid drug denile, and recent advances. Reflecting the great progress made in recent years in this field, this publication will be of great benefit to a better understanding, diagnosis and management of cutaneous drug eruptions, not only for general physicians, dermatologists and clinical allergologists, but also for nurses and scientists.

The skin is one of the most frequently involved organs in adverse drug reactions. Occurring with an incidence of 1-5% for certain types of drugs, cutaneous drug eruptions are mostly benign in nature, and comprise the most common popular type of eruption and urticaria. However, over one third of them require hospital treatment, leading to a considerable burden for the health care system.

In this book, a selected group of experts provide an up-to-date, condensed, and clinically relevant overview of the field of cutaneous drug eruptions, ranging from epidemiology and genetic predisposition to available therapeutic measures, including rapid drug denile, and recent advances. Reflecting the great progress made in recent years in this field, this publication will be of great benefit to a better understanding, diagnosis and management of cutaneous drug eruptions, not only for general physicians, dermatologists and clinical allergologists, but also for nurses and scientists.
Guidelines for Authors

The Journal of Innate Immunity is a bimonthly published journal that aims to cover all aspects within the area of innate immunity, including evolutionary aspects, pathogen-host cell molecular interactions, host response and inflammation, complement and coagulation, microbial corruption of innate immunity, molecular genomics, development of vaccines and immune therapies. The journal features original papers (Research Articles, Clinical Investigations), Reviews/Mini Reviews, Letters to the Editors, Rapid Communications and Short Communications. Criteria for acceptance are quality, originality, and clarity. The Journal of Innate Immunity will not consider papers that are either preliminary or purely descriptive. Reports on clinical cases are accepted only if they provide novel insight into unresolved problems of innate immunity.

Submission

Only original papers written in English are considered. Manuscripts should be submitted online using the online submission website at www.karger.com/jin (the preferred word-processing package is MS-Word*).

Editorial Office:
Heiko Herwald, PhD
S. Karger AG
Editorial Office ‘Journal of Innate Immunity’
P. O. Box
CH–4009 Basel (Switzerland)
Tel. +41 61 306 13 57
Fax +41 61 306 14 34
E-Mail jin@karger.ch

Conditions

All manuscripts must be accompanied by a covering letter signed on behalf of all authors. Assurance should be given that the manuscript is not under simultaneous consideration by any other publication. Presentation of manuscripts should conform with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see N Engl J Med 1997;336:309–315).

All manuscripts are subject to editorial review. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the property of the Journal of Innate Immunity and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the authors’ responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Sections

In addition to regular papers, every issue of the journal will have a special section with a thematic focus. Contributions to these special topic sections are very welcome and authors are asked to contact the Editors-in-Chief or the responsible guest editors before submitting a manuscript in order to avoid clashes with other pending reviews.

Original Paper (Research Article/ Clinical Investigation): Submitted manuscripts should be fully documented reports of original research. They must describe significant and original observations.

Review: The normal maximum length of a Review is limited to 5–7 printed pages, i.e. approximately 20 manuscript pages (font 12, double spacing), including 1–3 figures and/or tables. The number of references should not exceed 50. Potential authors are asked to contact the editors before submitting their papers in order to avoid clashes with other pending reviews.

Letter to the Editor: Letters to the Editor concerning articles published in Journal of Innate Immunity may be submitted for publication. They should not be more than one printed page in length. If accepted, the authors of the articles concerned will be given the opportunity to reply.

Short Communication: The general arrangement for short communications is the same as for research papers. The text should also be divided into separate sections formally entitled introduction, methods, results, discussion. These should not be more than 3 printed pages in length including an abstract of up to 50 words.

Arrangement

Title page: The first page of each paper should include the title, the authors’ names, the institute(s) where the work was conducted, and a short title for use as a running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as an e-mail address.

Key words: For indexing purposes, a list of 3–10 key words in English is essential.

Abstract: Each paper needs an abstract of up to 200 words describing background, methods, results and conclusions.

Footnotes: Footnotes should be avoided. When necessary, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180×223 mm) or provide crop marks. Each illustration must be labelled with its number and the first author’s name. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling (final size), line art drawings one of 800–1,200 dpi. Figure files should not be embedded in a document file but submitted separately.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as ‘unpublished data’ and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org). Authors using EndNote® may choose the format setting for Intervirology for the correct format of references.

Examples


(b) Papers published only with DOIl numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.


Ethics

Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute’s committee on human research and thus meets the standards of the Declaration of Helsinki in its revised version of 1975 and its amendments of 1983, 1989, and 1996 [JAMA 1997;277:925–926]. Information suitable to reveal the subject’s identity is to be avoided. Further, they should also state that animal experiments conform to institutional standards. Copies of these guidelines and policy statements must be available for review by the editors if necessary.

Conflict of Interest

All forms of funding and support, including from companies, and any potential competing financial interests should be acknowledged in the cover letter to the editor when applicable. The statement has to be listed at the end of the article.
Page Charges
There are no page charges for 5 or fewer printed pages, which is equal to approx. 14 manuscript pages including references, figures and tables. Each additional complete or partial printed page is charged to the authors at CHF 325.–.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Author's Choice™
Karger’s Author’s Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.Karger.com. The option is available for a one-time fee of CHF 3000.–, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice™ service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH’s Public Access Policy is available at http://publicaccess.nih.gov/FAQ.htm#a1

Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution’s servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher's version, and must acknowledge the publisher's copyright. Authors selecting Karger's Author's Choice™ feature, however, are also permitted to archive the final, published version of their article, which includes copypasting and design improvements as well as citation links.

Color Illustrations
During the review process, the decision will be made as to which color illustrations of a manuscript can be reproduced free of charge. Authors will be informed of this at the time of acceptance of their paper.

Video Files
Video files for the Journal of Innate Immunity enhance the online versions. The printed journal remains the archival version. Since it does not contain video files, the latter can only be supplements which improve the reader’s understanding of the paper. In the printed version they should be replaced by a ‘typical’ figure. For further information, please refer to http://www.karger.com/jin_guidelines.

Copy Editing
All manuscripts accepted for publication by Karger are subject to copy editing. Changes introduced by the copy editor and/or questions will be marked in the manuscript so please be sure to check the proofs against the manuscript. The copy edited manuscript will be returned along with the proofs.

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer's errors, are charged to the author. No page proofs are supplied.

E-pub First
All articles are published electronically ahead of print with a DOI number and are supplemented later with the definite reference of the printed version. The articles become available immediately after the authors’ approval to publication, with the added advantage of being citable much earlier than in print. Authors can influence the time of appearance by promptly returning the proofs.

Reprints
An order form and a price list are sent with the proofs. Orders submitted after the release of an article in print are subject to considerably higher prices.
Contents

See the journal website for contents
Training the innate immunity: immunological memory in innate host defense

- Evolution and plant immunity
  Jos van der Meer, Max Cooper, Ofer Levy, Harold vd Burg, Uwe Conrath

- Innate immune memory in invertebrates
  Bruno Lemaître, David Schneider, Carolina Barillas-Mury, Joachim Kurtz

- Recognition in mammalian innate immunity
  Tom vd Poll, Gosse Adema, Ramnik Xavier

- Memory of mammalian innate immunity: Mo/Mf
  Alberto Mantovani, Mihai Netea, Bali Pulendran

- Memory of mammalian innate immunity: NK cells
  Eric Vivier, Lewis Lanier, Ulrich von Andrian

- Reprogramming innate immunity during infection
  David Kelvin, Gioacchino Natoli, Steven Kunkel

- Masterclass for young researchers

- Poster sessions

For registration & programme visit:
www.innateimmunity.nl
This Symposium will be of interest to critical care physicians and nurses, infectious disease specialists, microbiologists, immunologists, intensivists, pulmonologists and others with an interest in the field of sepsis.

"Ce n’est pas assez d’avoir l’esprit bon, mais le principal est de l’appliquer bien."

translated: “It’s not enough to have a good mind; the most important thing is to use it well”

René Descartes (1596—1650)

Abstract deadline opens 1 May 2012
Abstract deadline closes 3 August 2012

For more information please visit:
www.sepsisforum.org
Evolution of Anti-HIV Drug Resistance – Interpretation and Its Therapeutic Progress

Editors
Lutz Guertler
Rolf Kaiser
Martin Stuermer

HIV Drug Resistance Determination and Treatment of Patients

Author Index/Subject Index

www.karger.com/int

Please send: ___ copy/ies
Postage and handling free with prepayment

Payment:
Please charge to my credit card
☐ American Express ☐ Diners
☐ MasterCard ☐ Visa

Card No.: ____________________________
Exp. date: ____________________________

CVV/CVC: (3 digits in the signature field on the back of Visa and MasterCard)
☐ Check enclosed ☐ Please bill me

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

A valuable update on Anti-HIV Drug Resistance

Evolution of Anti-HIV Drug Resistance – Interpretation and Its Therapeutic Progress

Contents

Introduction
HIV and Drug Resistance – Interpretation and Therapeutic Progress: Guertler, L.

Basic Principles of HIV
HIV Types, Groups, Subtypes and Recombinant Forms: Errors in Replication, Selection Pressure and Quasispecies: Eberle, J.; Guertler, L.
Targets for Inhibition of HIV Replication: Entry, Enzyme Action, Release and Maturation: Sierra-Aragón, S.; Walter, H.

Methods for HIV Resistance Determination and Interpretation
The HIVdb System for HIV-1 Genotypic Resistance Interpretation: Tang, M.W.; Liu, T.F.; Shafer, R.W.
Bioinformatical Assistance of Selecting Anti-HIV Therapies: Where Do We Stand?: Lengauer, T.

The XTrack System: Application and Advantage: Klümkait, T.
Description of Two Commercially Available Assays for Genotyping of HIV-1: Stuermer, M.; Reinheimer, C.

HIV Drug Resistance Determination and Treatment of Patients

Author Index/Subject Index

www.karger.com/int
Eosinophils in Allergy and Related Diseases
Workshop, Tokyo, June 2011: Proceedings

Editors

Contents

Preface: Ohno, I.

Plenary Review
Pathophysiologic Role of Histamine: Evidence Clarified by Histidine Decarboxylase Gene Knockout Mice: Ohno, I. et al.

Original Papers
Murine T Cell-Derived Contractile Activity for Bronchial Smooth Muscle Cells: Abe, A. et al.
Eosinophil Granular Proteins Damage Bronchial Epithelial Cells Infected with Respiratory Syncytial Virus: Kata, M. et al.
Alternaria Fungus Induces the Production of GM-CSF, Interleukin-6 and Interleukin-8 and Calcium Signaling in Human Airway Epithelium through Protease-Activated Receptor 2: Matsuzaki, Y. et al.
Nfat1 and Nfat2 Differentially Regulate Il-17a Expression in Human T Cells: Kaminuma, O. et al.

Higher Sensitivity of Male CD4+ T Cells to Suppressive Effects of CD8+ T Cells on Il-5 Production Compared to Female CD4+ T Cells: Okayama, K. et al.
Roles of Crth2+ CD4+ T Cells in Immunoglobulin G4-Related Lacrimal Gland Enlargement: Saito, Y. et al.
Elevated Levels of Interleukin-33 in the Nasal Secretions of Patients with Allergic Rhinitis: Asaka, D. et al.
1,25-Dihydroxyvitamin D3 Upregulates Possible Regulatory Role of Galectin-9 on Human Airway Inflammation in Mice: Kato, M. et al.
Inhibition of Allergen-Induced Airway inflammation by Low Dose Oral Immuno-therapy with Transgenic Rice Seeds Independently of Immunoglobulin E Synthesis: Saeki, M. et al.

Novel Insights from Clinical Practice
Elevated Numbers of Cells Producing Interleukin-5 and Interleukin-10 in a Boy with Kimura Disease: Hosoki, K. et al.
Eosinophilic Gastroenteritis due to Cow’s Milk Allergy Presenting with Acute Pancreatitis: Suzuki, S. et al.
Eosinophilic Gastrointestinal Disorder in an Infant with Feeding Dysfunction: Yamada, Y. et al.

Reviews
Obesity and Eosinophilic Inflammation: Does Leptin Play a Role?: Takeda, M. et al.
Neutrophilic Inflammation in Severe Asthma: Nakagomi, K. et al.

Abstracts of Lectures at the Workshop
List of Lectures by Speakers Who Have Not Submitted Their Manuscripts
Author Index
Subject Index

www.karger.com/iaa

Eosinophils in Allergy and Related Diseases
Workshop, Tokyo, June 2011: Proceedings
IV + 106 p., 42 fig., 8 in color, 7 tab., soft cover, 2012
CHF 39.– / EUR 33.– / USD 46.00
Prices subject to change
EUR price for Germany, USD price for USA only

International Archives of Allergy and Immunology
Vol. 158, Suppl. 1 (2012)
Included in subscription

Please send: ___ copy/ies
Postage and handling free with prepayment

Payment:
Please charge to my credit card
☐ American Express ☐ Diners
☐ MasterCard ☐ Visa

Card No.: ____________
Exp. date: ____________

CVV/CVC: ___ (3 digits in the signature field on the back of Visa and MasterCard)
☐ Check enclosed ☐ Please bill me

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.

Fax: +41 61 306 12 34
S. Karger AG, P.O. Box, CH–4009 Basel (Switzerland)
E-Mail orders@karger.ch, www.karger.com

Name/Address:

Date:

Signature:
Adverse Cutaneous Drug Eruptions

Editor
Lars E. French

Contents
Preface: French, L.E.

Author Index
Subject Index

Adverse Cutaneous Drug Eruptions

Lars E. French

The skin is one of the most frequently involved organs in adverse drug reactions. Occurring with an incidence of 1–5% for certain types of drugs, cutaneous drug eruptions are mostly benign in nature, and comprise the mucosal and the extracutaneous type of eruption and urticaria. However, about one third of them require hospital treatment, leading to a considerable burden for the health care system.

In this book, a selected group of experts provides an up-to-date, condensed and clinically relevant overview of the field of cutaneous drug eruptions, ranging from epidemiology and genetic predisposition to available therapeutic measures, including rapid drug detection. Reflecting the great progress made in recent years in this field, this publication will be a useful tool for a better understanding, diagnosis and management of cutaneous drug eruptions, not only for general physicians, dermatologists and clinical allergologists, but also for nurses and scientists.
The multiple functions and activities of host defence peptides, described in the reviews of this theme issue are presented. The picture also illustrates LL-37 (upper) and β-defensin 1. (PDB ID 2K60 and 1IJV, respectively)

Cover illustration
The multiple functions and activities of host defence peptides, described in the reviews of this theme issue are presented. The picture also illustrates LL-37 (upper) and β-defensin 1. (PDB ID 2K60 and 1IJV, respectively)